AcelRx Pharma (ACRX) Announces Positive Data from ARX-04 Phase 3 in Elderly Patients and Patients with Organ Impairment
Tweet Send to a Friend
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that in an open-label Phase 3 trial (SAP303), investigational product candidate ARX-04 (sufentanil sublingual ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
